Expression and characterization of cynomolgus monkey cytochrome cyp3a4 in a novel human embryonic kidney cell-based mammalian systems

Drug Metabolism and Disposition

Volumn 42, Issue 3, 2014, Pages 369-376

  Selvakumar, Sindhuja ^a   Bhutani, Priyadeep ^a   Ghosh, Kaushik ^a   Krishnamurthy, Prasad ^a   Kallipatti, Sanjith ^a   Selvam, Sabariya ^a   Ramarao, Manjunath ^c   Mandlekar, Sandhya ^c   Sinz, Michael W ^a   Rodrigues, A David ^b   Subramanian, Murali ^a  

^a SYNGENE INTERNATIONAL LTD   (India)

^b BRISTOL MYERS SQUIBB   (United States)

^c Bristol Myers Squibb India Ltd BBRC   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; CLONING, MOLECULAR; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HEK293 CELLS; HUMANS; KINETICS; MACACA FASCICULARIS; MICROSOMES, LIVER; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; SPECIES SPECIFICITY; SUBSTRATE SPECIFICITY; TRANSFECTION;

EID: 84893870106     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.055491     Document Type: Article

References (32)

1. Akabane T, Tabata K, Kadono K, Sakuda S, Terashita S, and Teramura T (2010) A comparison of pharmacokinetics between humans and monkeys. Drug Metab Dispos 38:308-316.
2. Carr B, Norcross R, Fang Y, Lu P, Rodrigues AD, Shou M, Rushmore T, and Booth-Genthe C (2006) Characterization of the rhesus monkey CYP3A64 enzyme: species comparisons of CYP3A substrate specificity and kinetics using baculovirus-expressed recombinant enzymes. Drug Metab Dispos 34:1703-1712.
3. Chiou WL and Buehler PW (2002) Comparison of oral absorption and bioavailablity of drugs between monkey and human. Pharm Res 19:868-874.
4. Durocher Y, Perret S, and Kamen A (2002) High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res 30:E9.
5. Emoto C, Iwasaki K, Koizumi R, Utoh M, Murayama K, Uno Y, and Yamazaki H (2011) Species difference between cynomolgus monkeys and humans on cytochrome P450 2D and 3Adependent drug oxidation activities in liver microsomes. J Health Sci 57:164-170.
6. Emoto C, Yoda N, Uno Y, Iwasaki K, Umehara K, Kashiyama E, and Yamazaki H (2013) Comparison of p450 enzymes between cynomolgus monkeys and humans: p450 identities, protein contents, kinetic parameters, and potential for inhibitory profiles. Curr Drug Metab 14: 239-252.
7. Iwasaki K, Murayama N, Koizumi R, Uno Y, and Yamazaki H (2010) Comparison of cytochrome P450 3A enzymes in cynomolgus monkeys and humans. Drug Metab Pharmacokinet 25: 388-391.
8. Iwasaki K and Uno Y (2009) Cynomolgus monkey CYPs: a comparison with human CYPs. Xenobiotica 39:578-581.
9. Komura H and Iwaki M (2008) Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates. J Pharm Sci 97:1775-1800.
10. Mankowski DC, Laddison KJ, Christopherson PA, Ekins S, Tweedie DJ, and Lawton MP (1999) Molecular cloning, expression, and characterization of CYP2D17 from cynomolgus monkey liver. Arch Biochem Biophys 372:189-196.
11. Nishimura T, Amano N, Kubo Y, Ono M, Kato Y, Fujita H, Kimura Y, and Tsuji A (2007) Asymmetric intestinal first-pass metabolism causes minimal oral bioavailability of midazolam in cynomolgus monkey. Drug Metab Dispos 35:1275-1284.
12. Nishimuta H, Sato K, Yabuki M, and Komuro S (2011) Prediction of the intestinal first-pass metabolism of CYP3A and UGT substrates in humans from in vitro data. Drug Metab Pharmacokinet 26:592-601.
13. Ohtsuka T, Yoshikawa T, Kozakai K, Tsuneto Y, Uno Y, Utoh M, Yamazaki H, and Kume T (2010) Alprazolam as an in vivo probe for studying induction of CYP3A in cynomolgus monkeys. Drug Metab Dispos 38:1806-1813.
14. Omura T and Sato R (1964) The Carbon Monoxide-Binding Pigment of Liver Microsomes. I. Evidence for Its Hemoprotein Nature. J Biol Chem 239:2370-2378.
15. Parkinson A, Kazmi F, Buckley DB, Yerino P, Paris BL, Holsapple J, Toren P, Otradovec SM, and Ogilvie BW (2011) An evaluation of the dilution method for identifying metabolismdependent inhibitors of cytochrome P450 enzymes. Drug Metab Dispos 39:1370-1387.
16. Patki KC, Von Moltke LL, and Greenblatt DJ (2003) In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos 31:938-944.
17. Pham PL, Perret S, Cass B, Carpentier E, St-Laurent G, Bisson L, Kamen A, and Durocher Y (2005) Transient gene expression in HEK293 cells: peptone addition posttransfection improves recombinant protein synthesis. Biotechnol Bioeng 90:332-344.
18. Rodrigues AD (1999) Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57:465-480.
19. Rodrigues AD, Mulford DJ, Lee RD, Surber BW, Kukulka MJ, Ferrero JL, Thomas SB, Shet MS, and Estabrook RW (1995) In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices. Drug Metab Dispos 23:765-775.
20. Sietsema WK (1989) The absolute oral bioavailability of selected drugs. Int J Clin Pharmacol Ther Toxicol 27:179-211.
21. Takahashi M, Washio T, Suzuki N, Igeta K, and Yamashita S (2009) The species differences of intestinal drug absorption and first-pass metabolism between cynomolgus monkeys and humans. J Pharm Sci 98:4343-4353.
22. Takahashi M, Washio T, Suzuki N, Igeta K, and Yamashita S (2010) Investigation of the intestinal permeability and first-pass metabolism of drugs in cynomolgus monkeys using singlepass intestinal perfusion. Biol Pharm Bull 33:111-116.
23. Tracy TS (2003) Atypical enzyme kinetics: their effect on in vitro-in vivo pharmacokinetic predictions and drug interactions. Curr Drug Metab 4:341-346.
24. Uehara S, Murayama N, Nakanishi Y, Zeldin DC, Yamazaki H, and Uno Y (2011) Immunochemical detection of cytochrome P450 enzymes in liver microsomes of 27 cynomolgus monkeys. J Pharmacol Exp Ther 339:654-661.
25. Uehara S, Murayama N, Yamazaki H, and Uno Y (2010) A novel CYP2A26 identified in cynomolgus monkey liver metabolizes coumarin. Xenobiotica 40:621-629.
26. Uno Y, Hosaka S, Matsuno K, Nakamura C, Kito G, Kamataki T, and Nagata R (2007) Characterization of cynomolgus monkey cytochrome P450 (P450) cDNAs: is CYP2C76 the only monkey-specific P450 gene responsible for species differences in drug metabolism? Arch Biochem Biophys 466:98-105.
27. Uno Y, Iwasaki K, Yamazaki H, and Nelson DR (2011) Macaque cytochromes P450: nomenclature, transcript, gene, genomic structure, and function. Drug Metab Rev 43:346-361.
28. Uno Y, Uehara S, Kohara S, Murayama N, and Yamazaki H (2010) Cynomolgus monkey CYP2D44 newly identified in liver, metabolizes bufuralol, and dextromethorphan. Drug Metab Dispos 38:1486-1492.
29. Venkatakrishnan K, von Moltke LL, Court MH, Harmatz JS, Crespi CL, and Greenblatt DJ (2000) Comparison between cytochrome P450 (P450) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos 28:1493-1504.
30. Walsky RL and Obach RS (2004) Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32:647-660.
31. Ward KW and Smith BR (2004) A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance. Drug Metab Dispos 32:603-611.
32. Yoda N, Emoto C, Date S, Kondo S, Miyake M, Nakazato S, Umehara K, and Kashiyama E (2012) Characterization of intestinal and hepatic P450 enzymes in cynomolgus monkeys with typical substrates and inhibitors for human P450 enzymes. Xenobiotica 42:719-730.